Compare HQ & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HQ | ANL |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Singapore | United States |
| Employees | 44 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.7M | 611.1M |
| IPO Year | N/A | 2022 |
| Metric | HQ | ANL |
|---|---|---|
| Price | $22.22 | $11.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.3M | 189.5K |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.29 | $0.88 |
| 52 Week High | $45.00 | $17.25 |
| Indicator | HQ | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 56.64 |
| Support Level | $21.30 | $9.00 |
| Resistance Level | $45.00 | $12.24 |
| Average True Range (ATR) | 3.52 | 1.35 |
| MACD | -0.90 | 0.17 |
| Stochastic Oscillator | 25.11 | 93.35 |
Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.